# A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide

> **NCT01977651** · PHASE4 · COMPLETED · sponsor: **Astellas Pharma Global Development, Inc.** · enrollment: 424 (actual)

## Conditions studied

- Metastatic Castration-resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT01977651
- **Lead sponsor:** Astellas Pharma Global Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-09-25
- **Primary completion:** 2016-02-01
- **Final completion:** 2019-01-11
- **Target enrollment:** 424 (ACTUAL)
- **Last updated:** 2024-12-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01977651

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01977651, "A Study to Evaluate the Potential Increased Risk of Seizures Among Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Treated With Enzalutamide". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01977651. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*